BNP Paribas announced its monthly declaration of voting rights and shares as of October 31, 2026. The bank reported a total of 1,101,600,607 shares and an equal number of voting rights. This update is part of regulatory compliance under French commercial law and financial market authority rules. The report provides transparency for shareholders and investors regarding the bank's capital structure.
The story on Groupe BNP Paribas' monthly voting rights declaration is presented with context from Pluang's Financials sector data. For readers following Financials, here is Pluang's market snapshot as of Nov 04, 2026 23:12 WIB: out of 142 priced US Financials stocks, 126 rose and 16 fell. Notably, RIOT rose 11.80% to USD 15.68 with nearly balanced buy-sell orders, contrasting with GLXY which dropped 11.53% to USD 14.89 despite 100% buy orders. AVAT also gained 9.99% to USD 0.96, supported by 76% buy activity and a typical hold time of 15 days.
Goldman Sachs Group, Inc. disclosed that it briefly held a combined stake exceeding 3% in Ontex Group NV shares as of October 27, 2026, with 566,115 voting rights and 1,965,157 financial instruments. However, by October 28, 2026, their combined posit...
Ontex disclosed that Goldman Sachs Group, Inc. crossed the 3% ownership threshold in Ontex shares on October 27, 2026, holding a combined total of 3.07% including voting rights and financial instruments. However, the next day, October 28, 2026, Goldm...
Neion Bio has appointed John A. Maga, Ph.D., as Head of Biologics and CMC to lead the development of biologic medicines using its Raptor platform, which produces proteins in transgenic chicken eggs. Maga brings over 25 years of biopharmaceutical expe...
The National Advertising Division (NAD) recommended that Good Life Meds discontinue claims about health benefits and personalization for its compounded Tirzepatide+ weight loss products after a challenge by Eli Lilly. NAD found that Good Life lacked ...
The Australia and New Zealand (ANZ) dental implants market, valued at $266 million in 2025, is projected to grow at a 5% CAGR to $393 million by 2033. Growth is driven by increasing demand for oral rehabilitation and prosthetic dentistry, especially ...
